Brainstorm Cell Therapeutics reported $13.25M in Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adamis Pharmaceuticals ADMP:US USD 10.93M 1.21M
Biogen BIIB:US USD 24.55B 300.1M
Brainstorm Cell Therapeutics BCLI:US USD 13.25M 5.71M
Cytokinetics CYTK:US USD 1.01B 61.19M
Gilead Sciences GILD:US USD 63.17B 614M
Halozyme Therapeutics HALO:US USD 1.84B 23.03M
Idera Pharmaceuticals IDRA:US USD 103.68M 77.38M